Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsDrreddyslaboratories

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Avoid Dr Reddys, says Sukhani

      Sudarshan Sukhani, s2analytics.com advises traders to avoid Dr Reddys.

    • Buy Dr Reddys Labs; sell Lupin: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Dr Reddys Laboratories while can sell Lupin.

    • Buy Dr Reddys Laboratories: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Dr Reddys Laboratories.

    • Short covering may be seen in Lupin, Dr Reddys: Gupta

      Short covering may be seen in Lupin and Dr Reddys, says Amit Gupta, ICICI Direct.

    • Buy Dr Reddys Laboratories: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Dr Reddys Laboratories.

    • Go long in Dr Reddys Lab, says Sukhani

      Go long in Dr Reddys Laboratories, says Sudarshan Sukhani of s2analytics.com.

    • KYI: Best stocks to trade as TCS, RIL rolls out Q3 results

      The market is gearing up for key earnings results next week including from Tata Consultancy Services Ltd (TCS) , Reliance Industries Ltd and ITC Ltd. Inflation data is also expected on Monday.

    • Buy Dr Reddys Laboratories: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the opinion that one can buy Dr Reddys Laboratories. For a very short-term trader, we could be looking at Rs 1950 and once the stock starts picking up momentum it could go anywhere.

    • Drugs that give Morgan high: Sun, Reddy's, Lupin, Glenmark

      Brokerage house Morgan Stanley has rated Dr Reddy‘s, Sun Pharma, Lupin and Glenmark as its top picks in the pharmaceuticals sector.

    • Dr Reddys top pick in pharma space, says PN Vijay

      Dr Reddys is a top pick in pharma space, says PN Vijay, Portfolio Manager, askpnvijay.com.

    • Prefer Ranbaxy Labs to Dr Reddys Labs: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can prefer Ranbaxy Laboratories to Dr Reddys Laboratories.

    • Hold Bajaj Auto, Dr Reddy's Labs: Rikesh Parikh

      Rikesh Parikh, Motilal Oswal Financial Services is of the view that one can hold Bajaj Auto, Dr Reddy‘s Laboratories.

    • Buying opportunity seen in Dr Reddys, says Sukhani

      Buying opportunity is seen in Dr Reddys at current prices, says Sudarshan Sukhani, s2analytics.com.

    • Go long in Dr Reddys Lab on dips: Amit Gupta

      Go long in Dr Reddys Laboratories on dips and look for a target of Rs 1,920 and keep stop loss below Rs 1750, says Amit Gupta, ICICI Direct.

    • Buy Dr Reddy's; Divis Lab, Biocon good bets: IIFL Cap

      Concentrating on the pharma space, Bino Pathiparampil of IIFL Capital told CNBC-TV18 the success of Biocon‘s oral insulin product deal would be a positive for the company. He also has a buy on Dr Reddy‘s and believes it should give a 25 percent plus upside in the next one year.

    • Check out: Prabhudas Lilladher's largecap and midcap picks

      Ajay Bodke of Prabhudas Lilladher says on ground implementation of reforms and the pace and extent of rate cuts, which the RBI could unveil post January, are the key events to watch, in addition to the contingence of the risk-on trade.

    • Buy SBI around Rs 2060, says Baliga

      Ambareesh Baliga, Market Expert advice traders to buy SBI around Rs 2060.

    • F&O market: ICICI Sec's strategy on Dr Reddy's, Bajaj Auto

      The Indian market has been resilient and rangebound over the last few sessions. In an interview to CNBC-TV18, Amit Gupta of ICICI Securities says, right now, the Nifty option premiums are quite subdued.

    • Accumulate Dr Reddys, Cipla on dip: Karun Mutha

      Accumulate Dr Reddys Laboratories and Cipla on dip, says Karun Mutha, HSBC Invest Direct.

    • Buy Dr Reddys Lab on declines, says Amit Gupta

      Buy Dr Reddys Laboratories on declines, says Amit Gupta, Head-Derivatives, ICICI Direct. The total open interest has been reduced by 24 percent in the last 1.5 month and the stock has just moved up from Rs 1700 to Rs 1760-1750 kind of levels. One can utilize the declines towards Rs 1760-1770 to go long for a target of Rs 1850.

    • Buy Dr Reddys Laboratories, says Amit Gupta

      One can buy Dr Reddys Laboratories and keep in portfolio because every now and then a signs of good amount of short covering happening whenever the stock falls by 4-5 percent. So that gives us a sense that it is eventually forming a good base before finally moving out further, says Amit Gupta of ICICI Direct.

    • Dr Reddys Laboratories has resistance at Rs 1740: Kulkarni

      Dr Reddys Laboratories has resistance at Rs 1740. As the stock stays below Rs 1740 it will clearly underperform the market, says Shardul Kulkarni of Angel Broking.

    • Buy JBF Ind, DCW, Dr Reddy Labs: Tater

      In CNBC-TV18's popular show Bull's Eye, Aashish Tater, FortuneWizard.com shares trading strategy of the day.

    • Bull's eye: Buy DCW, Century, Madras Cements, short SBI

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • See good upside in Dr Reddy's, Divis, Torrent Pharma: IIFL

      Bino Pathiparampil of IIFL is bullish on Dr. Reddy‘s, Divi‘s Laboratories and Torrent Pharma. These stocks have attractive valuations and strong growth prospects. "These three stocks have good upside even in this market," he told CNBC-TV18.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347